The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model.

Int J Mol Sci · 2025 · PMC12470015 · PMID 41009577

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Oxidized proteins in the MASLD group tended to be increased compared with the control group, and the empagliflozin/metformin combination showed a trend toward a decrease, though neither case reached statistical significance ( Figure 7 a).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.